Pfizer growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+10.4%+4.0%−9.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+22.1%+16.5%−21.5%
+24.6%+18.6%−18.5%
−5.9%+39.2%−11.6%
+0.2%+16.1%+5.7%
−0.3%+17.3%+12.1%
+46.7%+156.9%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PFIZER₹3,759.80

Pfizer Ltd.

· Pharma & Health
₹ CrorePeersGLAXOABBOTINDIAPOLYMEDONESOURCERAINBOWKIMSJUBLPHARMAVIJAYA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-9.6+4.0+10.4—
EBITDA Growth—-21.5+16.5+22.1—
EBIT Growth—-18.5+18.6+24.6—
Net Income Growth—-11.6+39.2-5.9—
Total Assets Growth—+5.7+16.1+0.2—
Total Equity Growth—+12.1+17.3-0.3—
Cash from Operations Growth——+156.9+46.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.